Bausch Health Patent-Cliff Exposure & CMS Drug Spending Portfolio
Bausch Health (Bridgewater, NJ): 114 reconciled FDA prescription therapies (72.6% 2025 to 2030 cliff risk), $3.52B 2024 CMS Part D & Medicaid spend, and 231 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Bridgewater, NJ |
| Reconciled FDA Portfolio Therapies | 114 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 72.6% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $3.52B |
| 2024 Medicare Part D Spend | $2.69B |
| 2024 Medicaid Spend | $828.0M |
| California HCAI SB 17 Filings | 231 WAC filings (max 85.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bausch Health / Bausch + Lomb FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBausch Health / Bausch + Lomb Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bausch Health / Bausch + Lomb 401(k) & Form 5500 Planerisa.meruai.co →